Publications


  • E. M. Salom, H.D. Homesley, C.A. Presant, J.Rutledge, M. O. Burrell, A. P. Garrett, A. Hallquist, M. Perree. 2010. Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC) –the role of new chemotherapy (CT) induced apoptosis assay. ASCO 2010.

    (Poster)(Abstract)

  • C. A. Presant, P. Whitworth, E. Salom, D. Davidson, K. M. Rogers, Swapnil Rajurkar, and A. Hallquist. 2010. Personalized cancer care: a new paradigm in oncology. Oncology Issues 25, 18-23.
    (Click Here)

  • K.S. Ballard, H.D. Homesley, C. Hodson, C.A. Presant, J.Rutledge, A.Hallquist, M. Perree. 2010. Endometrial Carcinoma In-Vitro Chemosensitivity Testing of Single and Combination Chemotherapy Regimens Using the Novel Microculture Kinetic (MiCK) Apoptosis Assay: Implications for Endometrial Cancer Treatment. J Gynecol Oncol, 21, 45-49.
    (Click Here)

  • Endometrial Mick Assay WAGO 2009
    (Click Here)

  • P. W. Whitworth, C. A. Presant, J. Rutledge, A. Hallquist, M. Perree, D. Agapitos - Chemosensitivity (CS) of patient (pt) breast cancer (BrCa) cells in vitro: correlation with prior chemotherapy (CT) and implications for personalized treatment planning
    (Click Here)
  
 
  • Garry Latimer, Cary A. Presant, Allan Hallquist, Mathieu Perree, and Despina Agapitos -
    The Value of Personalized Treatment (Rx) Planning (PTP): Cost Savings (sav) by the Microculture Kinetic (MiCK) chemosensitivity (CS) assay, Evidence from a Large American Self-insured Company (ASIC)
    (Click Here)

  • Cary A. Presant, Brandon Emilio and Linda Bosserman
    Patterns of Metastatic Disease Sites in Breast Cancer: Implications for Availability of Fresh Tumor
    Tissue for Personalized Cancer Treatment Planning in Metastatic Disease
    (Click Here)

  • Wintrobe’s Clinical Hematology 11th Addition, 2004 MiCK Assay.
    (Click Here) (Graph)

  • Kravtsov V (1994) A novel microculture kinetic (MiCK) assay for malignant cell growth and chemosensitivity. Eur J Cancer,30A,10,1564-1570
    (Click Here)
  • Natif O., M.Aronson,O.Medalia,T.Moldavsky,E.Sabo,I.Ringel,V.Kravtsov(1997) Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies.Int J Cancer, 70,297-301
    (Click Here)
  • Kravtsov V., Fabian I.(1996) Automated monitoring of apoptosis in suspension cell cultures. Lab Invest,74,557-570
    (Click Here)
  • Kravtsov V, Greer J,Whitlock J, Koury M (1998) Use of the microculture kinetic (MiCK) assay of apoptosis to determine chemosensitivities of leukemias. Blood,92,968-980
    (Click Here)
  • Kravtsov V, Daniel T, Koury M. (1999) Comparative analysis of several methodological approaches to the in vitro studies of cell apoptosis. Am J Pathology,155,1327-1339.
    (Click Here)
  • Zang J, Kravtsov V, Amarnath V, Picklo M, Graham D, Montine T. (2000) Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease. J Neurochem , 74,970-978.
    (Click Here)
  • V.Kravtsov, D.Martincic, J.Whitlock, M.Koury (1996). Tumor promoter phorbol miristate acetate modulates kinetics of drug-induced apoptosis in leukemia cells. The 38th ASH Meeting, Orlando. Blood, 88:67A
    (Click Here)
  • V.Kravtsov, M.Koury (1997). Induction of apoptosis in human myeloid leukemia cells by antimetabolites and anthracyclines. The 27th Annual Meeting of ISEH, Cannes.Exp Hematol, 25:852.
    (Click Here)
  • D.Martincic,V.Kravtsov,M.Koury,V.Avramis,J.Whitlock (1997) Deoxycytidine kinase expression and activity in Ara-C resistant bcell lines and samples from newly diagnosed acute leukemias. The 39th ASH Meeting, San-Diego, Blood, 90:71a
    (Click Here)
  • V. Kravtsov, J.Greer, J.Whitlock,M.Koury (1997)Use of the microculture kinetic (MiCK) assay of apoptosis to determine chemosensitivities of leukemiasThe 39th ASH Meeting, San-Diego, Blood,90:566a
    (Click Here)
  • V. Kravtsov, J.P. Greer, Y. Shyr, D.J.Haselton, J.A. Whitlock, S. Goodman, R.S. Stein, M.J. Koury (1998)Prediction of survival and responses to chemotherapy in acute myelogeneous leukemia (AML) by the microculture kinetic (MiCK) assay of apoptosis. The 40th ASH Meeting, Miami Beach.Blood,92:677a
    (Click Here)
  • D.Martincic, V.Kravtsov,M.Koury,J.A.Whitlock (1998). Low level of deoxycytidine kinase expression and activity is common in samples from newly diagnosed acute myelogenous leukemia resistant to ara-C. The 40th ASH Meeting, Miami Beach.Blood,92:390a
    (Click Here)
  • V.Kravtsov,V.Priego, J.Reilly, H.Sethi, J.Cooke,W.Smith,M.Koury (2000) Chemotherapy of myeloid leukemia directed by a microculture kinetic assay for apoptosis. The 42nd ASH Meeting. Blood, 96:3129.
    (Click Here)
  • S. Kubba, V Kravtsov, M.Koury, R.Kim (2000). Single nucleotide polymorphisms in MDR1 gene among patients with acute leukemia: correlation of drug-induced apoptosis to MDR1 genotype .The 42nd ASH Meeting. Blood, 96:
    (Click Here)
  • R.Schultz, M.Rothenberg, M.Koury, W.Hankins, V.Kravtsov (2000) Sequence dependence using combination of Alimta (pemetrexed disodium, LY231514,MTA), gemcitabine, and oxaliplatin in human colorectal carcinoma cell lines. Procedings of the 11th NCI-EORTC-AACR Symposium. Clin Cancer Res, 6:1078.
    (Click Here)
  • V.Kravtsov, J. Greer, Y. Shyr, J. Whitlock, T., T.McCurley, Goodman, R. Stein, S.Krantz, M. Koury (2001) Prediction of survival in acute non-lymphocytic leukemia (AML). The 43rd ASH Meeting, Orlando, Blood,98:214b
    (Click Here)
  • V Kravtsov, D Martincic, J Whitlock, J Greer, M Koury (1999) Disparity Between Morphological Evidence of Apoptosis and Internucleosomal DNA Fragmentation in Hematologic Malignancies
    (Click Here)